Johnson & Johnson ’s Covid-19 vaccine contributed $100 million to the company’s sales growth in the latest quarter, as U.S. health authorities re-evaluate the vaccine during a pause amid safety concerns.
As vaccination campaigns help ease the pandemic’s severity, Johnson & Johnson’s results from its other business lines showed a trend toward normality compared with the tumultuous first months of 2020.
Johnson & Johnson’s pharmaceutical revenue grew 10% year over year. Revenue from drugs such as Darzalex, for multiple myeloma, Stelara, for inflammatory diseases, and Erleada, for prostate cancer, helped drive the improvement.
